US-headquartered blockchain security player CertiK with significant operations in China raised $37 million in its Series B round. In a separate development, Westlake Therapeutics has bagged 100 million yuan ($15 million) in a new round.
CertiK bags $37m in Series B
US-headquartered blockchain security player CertiK with significant operations in China raised $37 million in its Series B round, per a company statement on Thursday.
The Series B round was co-led by Xiaomi’s Shunwei Capital and technology-focused investment manager Coatue Management with the participation of Coinbase Ventures, an investment arm of US cryptocurrency major Coinbase.
CertiK’s existing backers include Yale University, IDG Capital, Legend Star, Lightspeed China Partners, Danhua Capital and Tsing-Yuan Capital.
Proceeds from the funding will be used to expand its product base, security, and team.
Established in 2018 by professors of Yale University and Columbia University, CertiK uses AI to audit and monitor blockchain protocols and smart contracts. It claims to have so far served over 1,000 corporate clients.
Sequoia, Eight Roads back Westlake Therapeutics
Hangzhou-headquartered cell therapy company Westlake Therapeutics has raised 100 million yuan ($15 million) in a new round, it said on a WeChat post on Thursday.
Existing investors Sequoia Capital China and Eight Road Ventures jointly led the round, with the participation of CD Capital and Hofon Capital.
In March 2021, Sequoia, Eight Roads and CD had invested in the company. And prior to that, in June 2020, the company had bagged funding from Hofon along with others like Shaanxi Investment.
Launched in 2020, Westlake plans to use the corpus to expand its clinical trials, spruce up its R&D center, hire talent, and clinch strategic partnerships. It works on areas of cancers, and autoimmune and metabolic disorders, among others.